TY - JOUR
T1 - Artificial Intelligence in Advancing Inflammatory Bowel Disease Management
T2 - Setting New Standards
AU - Labarile, Nunzia
AU - Vitello, Alessandro
AU - Sinagra, Emanuele
AU - Nardone, Olga Maria
AU - Calabrese, Giulio
AU - Bonomo, Federico
AU - Maida, Marcello
AU - Iacucci, Marietta
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/7
Y1 - 2025/7
N2 - Introduction: Artificial intelligence (AI) is increasingly being applied to improve the diagnosis and management of inflammatory bowel disease (IBD). Aims and Methods: We conducted a narrative review of the literature on AI applications in IBD endoscopy, focusing on diagnosis, disease activity assessment, therapy prediction, and detection of dysplasia. Results: AI systems have demonstrated high accuracy in assessing endoscopic and histological disease activity in ulcerative colitis and Crohn’s disease, with performance comparable to expert clinicians. Machine learning models can predict response to biologics and risk of complications. AI-assisted technologies like confocal laser endomicroscopy enable real-time histological assessment. Computer-aided detection systems improve identification of dysplastic lesions during surveillance. Challenges remain, including need for larger datasets, external validation, and addressing potential biases. Conclusions: AI has significant potential to enhance IBD care by providing rapid, objective assessments of disease activity, predicting outcomes, and assisting in dysplasia surveillance. However, further validation in diverse populations and prospective studies are needed before widespread clinical implementation. With ongoing advances, AI is poised to become a valuable tool to support clinical decision-making and improve patient outcomes in IBD. Addressing methodological, regulatory, and cost barriers will be crucial for the successful integration of AI into routine IBD management.
AB - Introduction: Artificial intelligence (AI) is increasingly being applied to improve the diagnosis and management of inflammatory bowel disease (IBD). Aims and Methods: We conducted a narrative review of the literature on AI applications in IBD endoscopy, focusing on diagnosis, disease activity assessment, therapy prediction, and detection of dysplasia. Results: AI systems have demonstrated high accuracy in assessing endoscopic and histological disease activity in ulcerative colitis and Crohn’s disease, with performance comparable to expert clinicians. Machine learning models can predict response to biologics and risk of complications. AI-assisted technologies like confocal laser endomicroscopy enable real-time histological assessment. Computer-aided detection systems improve identification of dysplastic lesions during surveillance. Challenges remain, including need for larger datasets, external validation, and addressing potential biases. Conclusions: AI has significant potential to enhance IBD care by providing rapid, objective assessments of disease activity, predicting outcomes, and assisting in dysplasia surveillance. However, further validation in diverse populations and prospective studies are needed before widespread clinical implementation. With ongoing advances, AI is poised to become a valuable tool to support clinical decision-making and improve patient outcomes in IBD. Addressing methodological, regulatory, and cost barriers will be crucial for the successful integration of AI into routine IBD management.
KW - artificial intelligence
KW - Crohn’s disease
KW - inflammatory bowel disease
KW - ulcerative colitis
UR - https://www.scopus.com/pages/publications/105011530839
U2 - 10.3390/cancers17142337
DO - 10.3390/cancers17142337
M3 - Review article
AN - SCOPUS:105011530839
SN - 2072-6694
VL - 17
JO - Cancers
JF - Cancers
IS - 14
M1 - 2337
ER -